We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
98 hedge funds and large institutions have $38.6M invested in Galectin Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,729% more call options, than puts
Call options by funds: $5.72M | Put options by funds: $313K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3.58% more ownership
Funds ownership: 17.94% → 21.52% (+3.6%)
1% more funds holding
Funds holding: 97 → 98 (+1)
19% less capital invested
Capital invested by funds: $47.9M → $38.6M (-$9.3M)
Holders
98
Holders Change
+1
Holders Change %
+1.03%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
31
Reduced
23
Closed
15
Calls
$5.72M
Puts
$313K
Net Calls
+$5.41M
Net Calls Change
-$328K
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.88M |
| 2 |
Millennium Management
New York
|
+$1.71M |
| 3 |
Two Sigma Investments
New York
|
+$1.37M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$883K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$818K |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$592K |
| 2 |
Morgan Stanley
New York
|
-$532K |
| 3 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$423K |
| 4 |
Goldman Sachs
New York
|
-$373K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$343K |
